About CymaBay Therapeutics
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: CBAY
- Previous Close: $2.96
- 50 Day Moving Average: $2.15
- 200 Day Moving Average: $1.97
- 52-Week Range: $1.02 - $3.38
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.15
- P/E Growth: 0.00
- Market Cap: $69.40M
- Outstanding Shares: 23,447,000
- Beta: 1.17
- Return on Equity: -136.00%
- Return on Assets: -76.09%
Companies Related to CymaBay Therapeutics:
- Debt-to-Equity Ratio: 0.67%
- Current Ratio: 3.16%
- Quick Ratio: 3.16%
What is CymaBay Therapeutics' stock symbol?
CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."
Where is CymaBay Therapeutics' stock going? Where will CymaBay Therapeutics' stock price be in 2017?
2 brokers have issued 12-month price objectives for CymaBay Therapeutics' stock. Their predictions range from $6.00 to $6.00. On average, they anticipate CymaBay Therapeutics' share price to reach $6.00 in the next twelve months.
When will CymaBay Therapeutics announce their earnings?
CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.
Who owns CymaBay Therapeutics stock?
CymaBay Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Kingdon Capital Management L.L.C. (4.01%), J. Goldman & Co LP (1.41%) and Renaissance Technologies LLC (0.50%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Emster Kurt Von, Robert James Wills, Sujal Shah and Wart Harold Van.
Who sold CymaBay Therapeutics stock? Who is selling CymaBay Therapeutics stock?
CymaBay Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C. and Renaissance Technologies LLC.
Who bought CymaBay Therapeutics stock? Who is buying CymaBay Therapeutics stock?
CymaBay Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including J. Goldman & Co LP. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Emster Kurt Von, Robert James Wills, Sujal Shah and Wart Harold Van.
How do I buy CymaBay Therapeutics stock?
Shares of CymaBay Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of CymaBay Therapeutics stock cost?
One share of CymaBay Therapeutics stock can currently be purchased for approximately $2.96.